LexaGene
LexaGene Reports $58K in Fiscal Q4 Revenues, Spurred by MiQLab Launch
The Beverly, Massachusetts-based firm noted that all revenue from its MiQLab was generated from US customers.
In Brief This Week: Abbott Laboratories, LexaGene, Caris Life Sciences, SQI Diagnostics, and More
News items for the in vitro diagnostics industry for the week of March 1, 2021.
LexaGene Open-Access Syndromic Panel Platform Lets Labs Customize Targets, Including SARS-CoV-2
Premium
The MiQLab system can look for 27 different targets, allowing the detection of SARS-CoV-2 as well as the determination of specific variants.
LexaGene Shifts Gears to Prepare Viral RT-qPCR Panel for FDA Emergency Submission
After validating its pathogen detection platform for multiple viruses, the firm aims to initially offer a point-of-care diagnostic testing panel by the third quarter.
LexaGene Closes C$6.6M Financing Round
The firm will use the net proceeds for research and development, marketing, and general corporate purposes to help commercialize its LX Analyzer technology.